The effect and safety of levodopa alone versus levodopa sparing therapy for early Parkinson's disease: a systematic review and meta-analysis.

Abstract

BACKGROUND:

The best choice between levodopa alone and levodopa sparing medications for early Parkinson's disease (PD) remains controversial. We aimed to evaluate the effect and safety of levodopa alone and levodopa sparing therapy in symptom relief, neuroimage results and complications.

METHODS:

A systematic search was performed in PubMed, The Cochrane Library, EMBASE, and Web of Science for randomized controlled trials of early PD patients comparing levodopa-alone with levodopa-sparing therapy. The mean difference (MD) and the risk ratio (RR) were meta-analyzed.

RESULTS:

Twenty-three articles with 4913 patients were included. Significantly greater benefit was detected for the levodopa group in the changes of Unified Parkinson's Disease Rating Scale part II (p < 0.00001), III (p < 0.00001), and total (p < 0.00001) scores, and the between-group MD in part III score increased over time. The loss of the radioligands uptake in levodopa-alone group was also increasingly greater over time. Patients treated with levodopa alone were at higher risk for wearing-off (p < 0.001) and dyskinesia (p < 0.001), but the RR for dyskinesia between the two groups decreased after 2 years of follow-up.

CONCLUSION:

Levodopa-alone therapy might be superior in motor symptom relief than levodopa-sparing therapy for early PD patients, and the motor advantage of levodopa-alone might grow over time. Sparing therapy might be associated with less risk of wearing-off and dyskinesia, but the events between the two groups might not be different in the long run. Overall, levodopa alone therapy might bring more net benefit to early PD patients compared with levodopa sparing strategies. The clinical and imaging findings are conflicting, which requires further investigation.

• Authors: Yu-Tong Zhao, Li Liu, Yong Zhao, Zong-Yi Xie
• Journal: Journal of neurology (J Neurol) Vol. 269 Issue 4 Pg. 1834-1850 (Apr 2022) ISSN: 1432-1459 [Electronic] Germany
• PMID: 34652505 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Chemical References

• Antiparkinson Agents
• Levodopa

Topics

• Antiparkinson Agents (adverse effects)
• Dyskinesia, Drug-Induced (etiology)
• Humans
• Levodopa (adverse effects)
• Parkinson Disease (complications, drug therapy)